{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:03:46Z","timestamp":1790417026086,"version":"4.1.0"},"reference-count":27,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2017,2,28]],"date-time":"2017-02-28T00:00:00Z","timestamp":1488240000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1"},{"start":{"date-parts":[[2017,2,28]],"date-time":"2017-02-28T00:00:00Z","timestamp":1488240000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of PR China","doi-asserted-by":"crossref","award":["81273592"],"award-info":[{"award-number":["81273592"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of PR China","doi-asserted-by":"crossref","award":["81673509"],"award-info":[{"award-number":["81673509"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of PR China","doi-asserted-by":"crossref","award":["81573504"],"award-info":[{"award-number":["81573504"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of PR China","doi-asserted-by":"crossref","award":["81373487"],"award-info":[{"award-number":["81373487"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Pharm Ther"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1111\/jcpt.12505","type":"journal-article","created":{"date-parts":[[2017,2,28]],"date-time":"2017-02-28T10:43:44Z","timestamp":1488278624000},"page":"345-349","source":"Crossref","is-referenced-by-count":12,"title":["The influence of<i>CYP3A5*3<\/i>and<i>BCRPC421A<\/i>genetic polymorphisms on the pharmacokinetics of felodipine in healthy Chinese volunteers"],"prefix":"10.1155","volume":"42","author":[{"given":"Q.","family":"Xiang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Base for Clinical Trial; Peking University First Hospital; Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Base for Clinical Trial; Peking University First Hospital; Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Base for Clinical Trial; Peking University First Hospital; Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y. M.","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Base for Clinical Trial; Peking University First Hospital; Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,2,28]]},"reference":[{"key":"10.1111\/jcpt.12505-BIB0001|jcpt12505-cit-0001","unstructured":"Whitworth JA World Health Organization International Society of Hypertension Writing Group World Health Organization (WHO)\/International Society of Hypertension (ISH) statement on management of hypertension"},{"key":"10.1111\/jcpt.12505-BIB0002|jcpt12505-cit-0002","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/clpt.1985.160","article-title":"Felodipine kinetics in healthy men","volume":"38","author":"Edgar","year":"1985","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl 3","key":"10.1111\/jcpt.12505-BIB0003|jcpt12505-cit-0003","first-page":"16","article-title":"Clinical pharmacokinetics of felodipine","volume":"34","author":"Edgar","year":"1987","journal-title":"A summary. Drugs"},{"key":"10.1111\/jcpt.12505-BIB0004|jcpt12505-cit-0004","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0090-9556(25)08882-8","article-title":"Biotransformation of Felodipine in liver microsomes from rat, dog, and man","volume":"14","author":"B\u00e4\u00e4rnhielm","year":"1986","journal-title":"Drug Metab Dispos"},{"issue":"Suppl 3","key":"10.1111\/jcpt.12505-BIB0005|jcpt12505-cit-0005","doi-asserted-by":"publisher","first-page":"28","DOI":"10.2165\/00003495-198700343-00006","article-title":"Pharmacokinetics and haemodynamic effects of Felodipine as monotherapy in hypertensive patients","volume":"34","author":"Edgar","year":"1987","journal-title":"Drugs"},{"key":"10.1111\/jcpt.12505-BIB0006|jcpt12505-cit-0006","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/0140-6736(91)90872-M","article-title":"Interaction of citrus juices with Felodipine and nifedipine","volume":"337","author":"Bailey","year":"1991","journal-title":"Lancet"},{"key":"10.1111\/jcpt.12505-BIB0007|jcpt12505-cit-0007","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1124\/dmd.31.7.815","article-title":"The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective","volume":"31","author":"Bjornsson","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1111\/jcpt.12505-BIB0008|jcpt12505-cit-0008","first-page":"1","article-title":"Cytochrome P450 nomenclature, 2004","volume":"320","author":"Nelson","year":"2006","journal-title":"Methods Mol Biol"},{"key":"10.1111\/jcpt.12505-BIB0009|jcpt12505-cit-0009","doi-asserted-by":"publisher","first-page":"239","DOI":"10.2133\/dmpk.DMPK-12-RG-106","article-title":"The influence of UGT2B7, UGT1A8, MDR1, ALDH, ADH, CYP3A4 and CYP3A5 genetic polymorphisms on the pharmacokinetics of silodosin in healthy Chinese volunteers","volume":"28","author":"Wang","year":"2013","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1111\/jcpt.12505-BIB0010|jcpt12505-cit-0010","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/86882","article-title":"Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression","volume":"27","author":"Kuehl","year":"2001","journal-title":"Nat Genet"},{"key":"10.1111\/jcpt.12505-BIB0011|jcpt12505-cit-0011","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1124\/mol.62.1.162","article-title":"Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism","volume":"62","author":"Lin","year":"2002","journal-title":"Mol Pharmacol"},{"key":"10.1111\/jcpt.12505-BIB0012|jcpt12505-cit-0012","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2133\/dmpk.DMPK-11-RV-098","article-title":"Functional significance of genetic polymorphisms in P-glycoprotein (MDR1, ABCB1) and breast cancer resistance protein (BCRP, ABCG2)","volume":"27","author":"Ieiri","year":"2012","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1111\/jcpt.12505-BIB0013|jcpt12505-cit-0013","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.coph.2013.09.001","article-title":"OATP transporter-mediated drug absorption and interaction","volume":"13","author":"Tamai","year":"2013","journal-title":"Curr Opin Pharmacol"},{"key":"10.1111\/jcpt.12505-BIB0014|jcpt12505-cit-0014","doi-asserted-by":"publisher","first-page":"393","DOI":"10.2174\/1389200033489389","article-title":"Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data","volume":"4","author":"Benet","year":"2003","journal-title":"Curr Drug Metab"},{"key":"10.1111\/jcpt.12505-BIB0015|jcpt12505-cit-0015","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1021\/mp0500871","article-title":"P-glycoprotein recognition of substrates and circumvention through rational drug design","volume":"3","author":"Raub","year":"2006","journal-title":"Mol Pharm"},{"key":"10.1111\/jcpt.12505-BIB0016|jcpt12505-cit-0016","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1097\/FPC.0b013e32832cc7e9","article-title":"Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin","volume":"19","author":"Chen","year":"2009","journal-title":"Pharmacogenet Genomics"},{"key":"10.1111\/jcpt.12505-BIB0017|jcpt12505-cit-0017","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.tips.2005.11.007","article-title":"The function of breast cancer resistance protein in epithelial barriers, stem cells and milk secretion of drugs and xenotoxins","volume":"27","author":"Van Herwaarden","year":"2006","journal-title":"Trends Pharmacol Sci"},{"key":"10.1111\/jcpt.12505-BIB0018|jcpt12505-cit-0018","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1158\/1535-7163.MCT-07-2250","article-title":"Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-\/-\/Mdr1a\/1b-\/- (triple-knockout) and wild-type mice","volume":"7","author":"Marchetti","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1111\/jcpt.12505-BIB0019|jcpt12505-cit-0019","doi-asserted-by":"publisher","first-page":"650","DOI":"10.4161\/cbt.4.6.1731","article-title":"Effect of ABCG2 genotype on the oral bioavailability of topotecan","volume":"4","author":"Sparreboom","year":"2005","journal-title":"Cancer Biol Ther"},{"key":"10.1111\/jcpt.12505-BIB0020|jcpt12505-cit-0020","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.cca.2006.05.010","article-title":"Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males","volume":"373","author":"Zhang","year":"2006","journal-title":"Clin Chim Acta"},{"key":"10.1111\/jcpt.12505-BIB0021|jcpt12505-cit-0021","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1517\/phgs.5.3.243.29833","article-title":"Genetic variability in CYP3A5 and its possible consequences","volume":"5","author":"Xie","year":"2004","journal-title":"Pharmacogenomics"},{"key":"10.1111\/jcpt.12505-BIB0022|jcpt12505-cit-0022","first-page":"880","article-title":"The human intestinal cytochrome P450 \u2018pie\u2019","volume":"34","author":"Paine","year":"2006","journal-title":"Drug MetabDispos"},{"key":"10.1111\/jcpt.12505-BIB0023|jcpt12505-cit-0023","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1081\/DMR-120001392","article-title":"Summary of information on human CYP enzymes: human P450 metabolism data","volume":"34","author":"Rendic","year":"2002","journal-title":"Drug Metab Rev"},{"key":"10.1111\/jcpt.12505-BIB0024|jcpt12505-cit-0024","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1124\/dmd.30.12.1311","article-title":"Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions","volume":"30","author":"Yuan","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1111\/jcpt.12505-BIB0025|jcpt12505-cit-0025","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1097\/00008571-200112000-00005","article-title":"The genetic determinants of the CYP3A5 polymorphism","volume":"11","author":"Hustert","year":"2001","journal-title":"Pharmacogenetics"},{"key":"10.1111\/jcpt.12505-BIB0026|jcpt12505-cit-0026","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0009-9236(03)00168-1","article-title":"Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus","volume":"74","author":"Hesselink","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/jcpt.12505-BIB0027|jcpt12505-cit-0027","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1097\/01.TP.0000090753.99170.89","article-title":"Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients","volume":"76","author":"Thervet","year":"2003","journal-title":"Transplantation"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12505","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jcpt.12505\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T21:07:50Z","timestamp":1750021670000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jcpt.12505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,28]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,6]]}},"URL":"https:\/\/doi.org\/10.1111\/jcpt.12505","archive":["Portico"],"relation":{},"ISSN":["0269-4727"],"issn-type":[{"value":"0269-4727","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2,28]]}}}